EDIT Quote, Financials, Valuation and Earnings

EyePoint Pharmaceuticals has a net margin of -101870.49% compared to Editas Medicine's net margin of -278.99%. Editas Medicine's return on equity of -74.59% beat EyePoint Pharmaceuticals's return on equity of -50.67%.

Editas Medicine has a consensus price target of --, signalling upside risk potential of 179.9%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.45 which suggests that it could grow by 369.87%. Given that EyePoint Pharmaceuticals has higher upside potential than Editas Medicine, analysts believe EyePoint Pharmaceuticals is more attractive than Editas Medicine.

Editas Medicine has a beta of 1.864, which suggesting that the stock is 86.439% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.455, suggesting its more volatile than the S&P 500 by 45.456%.

Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

Editas Medicine quarterly revenues are $61K, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $10.5M. Editas Medicine's net income of -$62.1M is lower than EyePoint Pharmaceuticals's net income of -$29.4M. Notably, Editas Medicine's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 1.74x versus 7.90x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -101870.49% compared to Editas Medicine's net margin of -104.98%. Editas Medicine's return on equity of -74.59% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Editas Medicine has a consensus price target of --, signalling upside risk potential of 179.9%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 72.16%. Given that Editas Medicine has higher upside potential than Ionis Pharmaceuticals, analysts believe Editas Medicine is more attractive than Ionis Pharmaceuticals.

Editas Medicine has a beta of 1.864, which suggesting that the stock is 86.439% more volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Editas Medicine quarterly revenues are $61K, which are smaller than Ionis Pharmaceuticals quarterly revenues of $133.8M. Editas Medicine's net income of -$62.1M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Editas Medicine's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 1.74x versus 6.48x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -101870.49% compared to Editas Medicine's net margin of -246.3%. Editas Medicine's return on equity of -74.59% beat Regenxbio's return on equity of -69.62%.

Editas Medicine has a consensus price target of --, signalling upside risk potential of 179.9%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 393.27%. Given that Regenxbio has higher upside potential than Editas Medicine, analysts believe Regenxbio is more attractive than Editas Medicine.

Editas Medicine has a beta of 1.864, which suggesting that the stock is 86.439% more volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.

Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Editas Medicine quarterly revenues are $61K, which are smaller than Regenxbio quarterly revenues of $24.2M. Editas Medicine's net income of -$62.1M is lower than Regenxbio's net income of -$59.6M. Notably, Editas Medicine's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 1.74x versus 4.32x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -101870.49% compared to Editas Medicine's net margin of --. Editas Medicine's return on equity of -74.59% beat Cassava Sciences's return on equity of --.

Editas Medicine has a consensus price target of --, signalling upside risk potential of 179.9%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4815.25%. Given that Cassava Sciences has higher upside potential than Editas Medicine, analysts believe Cassava Sciences is more attractive than Editas Medicine.

Editas Medicine has a beta of 1.864, which suggesting that the stock is 86.439% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.

Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

Editas Medicine quarterly revenues are $61K, which are larger than Cassava Sciences quarterly revenues of --. Editas Medicine's net income of -$62.1M is lower than Cassava Sciences's net income of -$27.9M. Notably, Editas Medicine's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 1.74x versus 2.59x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.